An interventional study of Myota Metabolic Regulator in Pre-diabetes, sponsored by Myota GmbH. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by Myota GmbH · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Glucose Intolerance with a site in United Kingdom — 4 open to participants now, 7 under way, none of them phase 3. Glucose Intolerance · United Kingdom.
Among the 38 studies in Glucose Intolerance with a site in United Kingdom, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2022, is one of 25 with no phase, and was the 32nd registered.
793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.
Browse Glucose Intolerance studies →4 of the 38 studies in Glucose Intolerance with a site in United Kingdom are open now. Recruiting first, the newest first:
Leeds Beckett University · Sites in United Kingdom
Ages 18–40
University of Oxford · Sites in United Kingdom
Ages 6 mo–70 yrs
Chelsea and Westminster NHS Foundation Trust · Sites in United Kingdom
Ages 18–50 · Women only · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 18–60 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 68 Glucose Intolerance studies recruiting now, 13 (19%) set no upper age limit and 50 (74%) stop at 75 or younger; 9 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 2003; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 56 across 660 interventional studies indexed under Glucose Intolerance.
Median enrollment 40 across the 29 interventional studies, 400 across the 9 observational. Of the 28 that completed or were terminated, 5 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 38 have an industry lead sponsor. The 10 most frequent:
Myota GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Myota GmbH has 1 study filed under Glucose Intolerance — fewer than ten, so there is no comparison to draw.
3 of the studies in Glucose Intolerance with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125365University of OxfordUK Islet Autoantibody Registry | 2027-05-31 |
| NCT07073781Leeds Beckett UniversityProbiotics, Cognition and Metabolic Health in Young Adults With Overweight or Obesity | 2027-06-30 |
| NCT05753124Chelsea and Westminster NHS Foundation TrustEffect of Obesity, Diabetes and Bariatric Surgery on Pregnancy Outcomes | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Glucose Intolerance with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will investigate whether a powdered fibre mix helps maintain healthy blood glucose levels in participants with pre-diabetes, where high blood sugar is a risk of diabetes.
Pre-diabetes is characterised by high blood glucose levels, high plasma cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Dietary fibre consumption has been hypothesised to improve these metabolic parameters through the viscous properties, and the production of short-chain fatty acids (SCFA) in the intestine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
Dietary Supplement: Myota Metabolic Regulator
Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks. Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks.
The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
HbA1c levels
To compare the effect of Myota's Metabolic Regulator versus placebo on Hemoglobin A1c (HbA1c) levels
Time frame: 16 weeks
HbA1c levels
To compare the effect of Myota's Metabolic Regulator versus placebo on Hemoglobin A1c (HbA1c) levels
Time frame: 24 weeks
Insulin
To compare the effect of Myota's Metabolic Regulator versus placebo on blood insulin concentration.
Time frame: 16 and 24 weeks
Insulin sensitivity
To compare the effect of Myota's Metabolic Regulator versus placebo on insulin sensitivity as measured using ISI-OGTT.
Time frame: 16 weeks
Lipid profile
To compare the effect of Myota's Metabolic Regulator versus placebo on cholesterol \[total, low-density lipoprotein (LDL), high-density lipoprotein (HDL)\] and triglycerides levels.
Time frame: 16 and 24 weeks
Inflammatory markers
To compare the effect of Myota's Metabolic Regulator versus placebo on inflammatory markers (IL-6, IL-8, IL-10, CRP, TNF-a).
Time frame: 16 and 24 weeks
Blood pressure
To compare the effect of Myota's Metabolic Regulator versus placebo on diastolic and systolic blood pressure
Time frame: 16 and 24 weeks
Overall safety of the Myota Metabolic Regulator
Number of participants reporting adverse events (AEs) and serious adverse events (SAEs)
Time frame: Weeks 1-4
To investigate intervention adherence
A daily intervention adherence questionnaire will be used to assess the extent to which participant's adhered to the intervention. This will consist of two questions: Did you consume the full sachet of study product yesterday? Yes/No \[If no\] Why were you unable to take the product yesterday?
Time frame: 24 weeks
To investigate usability
A usability questionnaire will be administered to assess how easily participant's were able to use the intervention or placebo. This will consist of two statements: I found the supplement easy to take. Strongly disagree to Strongly agree (5 options) I would like to take this supplement in my normal daily life. Yes/no
Time frame: 16 and 24 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Aug 2023, 9 months.
Of 32 industry-sponsored interventional studies with no phase under Glucose Intolerance, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 37. This study's 9 months is below that.
Counting every sponsor, half of 285 studies reached it within 26 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myota GmbH